Hoya Vision Care expands power range of MiYOSMART spectacle lenses for myopia
The updated range of lenses feature expanded negative and cylindrical powers, thinner edge thickness, and wider frame options.
(Image credit: Adobe Stock / ©Miljan Živković)
Hoya Vision Care is expanding the power range of their MiYOSMART spectacle, now offering a broader range of negative and cylindrical powers to help more patients with high myopia manage the condition. The expanded range of lenses also feature slimmer edge thickness than previous iterations, and the larger diameter works with a wider selection of frames.1
The extension includes lenses that range from minus power of -13.00 diopters (D) to cylindrical power up to 4.00 D, accommodating both high myopia and astigmatism. The goal is to increase access to effective solutions for myopic children across the globe for improved visual outcomes.
“There is an urgent need to provide comprehensive solutions for children with high myopia as early as possible in order to reduce the risk of myopia-related complications in later life,” Natalia Vlasak, MD, MBA, Global Head of Medical and Scientific Affairs at HOYA Vision Care, said in a press release. “Slowing down the progression of myopia by just one diopter can reduce the risk of myopic maculopathy by 40%.2 With the extension of MiYOSMART’s power range to treat high myopia, it is not too late for these children to preserve their vision health for the future.”
Myopia is an epidemic, and high myopia carries extra risks, including increased incidence of myopic macular degeneration, retinal detachment, cataract, open angle glaucoma, vision loss, and additional complications associated with axial lengthening.3 While there is no treatment for myopia, it can be managed by slowing axial lengthening, typically via use of contact lenses or atropine drops.
"With the power range extension of MiYOSMART spectacle lenses to support children with high myopia, we are ensuring that it is never too late to help protect their vision for the future," said Vlasak in an exclusive quote. "Expanding access to MiYOSMART spectacle lenses to treat high myopia is a testament to HOYA's pledge to preserve the vision health of all children. We are dedicated to empowering Eye Care Professionals, parents, and policymakers to take urgent action for children’s eye health—continuously enhancing our myopia management solutions worldwide while advocating for vision-friendly habits, such as spending more time outdoors."
At this time, spectacle lenses for myopia management, including MiYOSMART, are not approved by the FDA or available for sale in the US. The FDA granted Breakthrough Device designation to SightGlass Vision’s Diffusion Optics Technology (DOT) spectacle lenses in February 2024,4 but the agency has not approved additional spectacle options for myopia management.
MiYOSMART spectacle lenses launched in 2018, and more than 10 million units have been purchased across 40 countries.1 Hoya Vision Care is dedicated to innovative solutions for myopia management that not only limit the progression of the disease, but they also hope encourage wear time in patients to limit myopia progression effectively. By increasing lens diameter to fit more frames and decreasing edge thickness, Hoya has improved the cosmetics of their lenses to head off concerns about the look of conventional high prescription lenses.
Hoya Vision Care plans to continue to evolve treatment solutions to improve access to effective and innovative myopia control tactics, according to a news release.
